Elotuzumab

Drug Profile

Elotuzumab

Alternative Names: BMS-901608; Empliciti; HuLuc63

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD319 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 21 Dec 2016 University of Arkansas in collaboration with Bristol-Myers Squibb and Altor Bioscience plans a phase II trial for Multiple myeloma in USA (NCT03003728)
  • 19 Dec 2016 University of Arkansas plans a phase II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater, Newly diagnosed) in USA (IV) (NCT03000634)
  • 05 Dec 2016 Interim efficacy and adverse events data from a phase II trial in Multiple myeloma (smoldering) released by Dana-Farber Cancer Institute
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top